Tradestie Institutional Equity Comparison Engine
CRBU vs MXCT โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
MXCT Overall Edge
MXCT Captures Institutional Edge (3โ0 Pillars ยท 5โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to MaxCyte, Inc. Common Stock (MXCT) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, CRBU trades at N/M Forward P/E with -1140.6% operating margin (-26.9% YoY revenue) versus MXCT at N/M Forward P/E and -85.5% operating margin (+48.7% YoY). In options structure, CRBU sits in BREAKDOWN (<1st %ile IV; Dealer Gamma Walls on Pro) against MXCT sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
CRBU N/M vs MXCT N/M Fwd P/E
Growth & Margin Winner
MXCT
Op Margin -1140.6% vs -85.5% ยท YoY -26.9% vs +48.7%
Momentum & Technical Winner
MXCT
1Y -84.4% vs -19.4% ยท 52W Pos 0% vs 63%
Options & Structure Winner
MXCT
BREAKDOWN (<1st %ile IV) vs UNCLASSIFIED (N/A IV)
CRBU
NASDAQ
Caribou Biosciences, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.28
-8.44% 1D
Market Cap
$33.5M
1M Return
-49.23%
1Y Return
-84.38%
Forward P/E
N/M
Unified AI Score
46.4 / 100
HOLD
Tech 25.0
Fund 48.0
Flow 68.0
Mom 59.0
MXCT
NASDAQ
MaxCyte, Inc. Common Stock
Services-Commercial Physical & Biological Research
$1.37
+7.03% 1D
Market Cap
$132.2M
1M Return
-4.2%
1Y Return
-19.41%
Forward P/E
N/M
Unified AI Score
41.7 / 100
SELL
Tech 46.0
Fund 52.0
Flow 62.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CRBU -84.38%
MXCT -19.41%
Spread: +64.97 pp (MXCT Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CRBU Revenue | MXCT Revenue | CRBU Op. Margin | MXCT Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2019 | $10M | $10M | -592.7% | -93.7% | MXCT |
| FY2020 | $10M | $20M | -292.2% | -71.6% | MXCT |
| FY2021 | $10M | $20M | -697.8% | -84.3% | MXCT |
| FY2022 | $10M | $30M | -768.2% | -95.2% | MXCT |
| FY2023 | $30M | $20M | -336.6% | -247.7% | MXCT |
| FY2024 | $10M | $20M | -1667.2% | -230.5% | MXCT |
| FY2025 | $10M | $20M | -1329.4% | -247.6% | MXCT |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CRBU | MXCT | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $33.5M | $132.2M | Larger Scale | MXCT |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -26.9% | +48.7% | Higher Growth | MXCT |
| Operating Margin (TTM) Profitability | -1140.6% | -85.5% | Higher Margin | MXCT |
| Net Profit Margin Profitability | 0.0% | -81.4% | Higher Margin | CRBU |
| Return on Equity (ROE) Capital Efficiency | -93.8% | -16.9% | Higher ROE | MXCT |
| 52-Week Range Position Momentum | 0% ($0โ$2) | 63% ($1โ$2) | Stronger Trend | MXCT |
| Beta / 30D Volatility Risk Regime | 1.56ฮฒ ยท 74% Vol | 1.19ฮฒ ยท 96% Vol | Lower Realized Risk | CRBU |
| Unified Institutional Score Composite Signal | 46.4 / 100 (HOLD) | 41.7 / 100 (SELL) | Higher Composite | CRBU |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CRBU vs MXCT Buy Guide
CRBU
BREAKDOWN
119d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
<1st %ile
IV Regime
Compressed (<25th %ile)
MXCT
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CRBU nor MXCT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.